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Abstract
Background: There are a lack of biomarkers which can be used to predict clinical outcomes for multiple sclerosis
(MS) patients receiving interferon beta (IFN-b). Thus the objective of this study was to characterize changes in CD4
+ T-lymphocyte expression in an unbiased manner following initiation of intramuscular (IM) IFN-b-1a treatment,
and then to verify those findings using marker-specific assays.
Methods: Peripheral blood specimens were collected from twenty MS patients before and after treatment with
intramuscular (IM) IFN-b-1a and were used for isolation of mononuclear cells (PBMCs). mRNA expression patterns of
negatively-selected CD4+ T-cells from the PBMCs were analyzed using microarray gene expression technology. IL-
12 and IL-23 receptor levels on PBMC-derived CD4+ T-cells were analyzed by flow cytometry. The phosphorylation
status of Stat4 was measured by performing densitometry on western blots.
Results: Microarray analyses demonstrated that mRNA expression of the IL-12Rb2 gene was uniformly up-regulated
in response to IFN-b-1a treatment and was associated with an increased number of IL-12Rb2+ CD4+ T-cells by flow
cytometry in 4 of 6 patients. This finding was substantiated by demonstrating that Stat4 phosphorylation, a
transcription factor for IL-12, was increased after treatment. Conversely, the number of IL-23R+ CD4+ T-cells was
decreased following treatment.
Conclusions: The IL-12 receptor shares a common subunit, the IL-12Rb2, with the IL-23 receptor. Both of these
receptors have a probable role in regulating IL-17 and TH-17 cells, important mediators of inflammation in multiple
sclerosis (MS). Thus, the changes in the numbers of CD4+ T-cells expressing these receptors in response to IFN-b-1a
treatment may point to an important mechanism of action for this drug, but further large scale studies are needed
to confirm these preliminary observations.
Background
Although interferon beta (IFN-b) therapies have been
commonly used as a treatment for multiple sclerosis
(MS) for over a decade, the mechanism of action
(MOA) of these therapeutic agents remains largely
undefined [1,2]. Given the central role of specific subsets
of CD4+ T-cells in the autoimmune process of
inflammatory lesion formation in MS, a frequently pro-
posed MOA for IFN-b’s involves changes in activities of
these cells. Although particular cytokines such as IL-12
and IL-23 and their receptors have been hypothesized to
be likely mediators of inflammation in MS, details con-
cerning receptor physiology in the treatment setting
remain sparse [3,4]. Therapy induced changes in CD4+
T-cell function have primarily been characterized in ani-
mal models of MS, and await verification in actual MS
patients [5].* Correspondence: fhu@wpahs.org1Center for Genomic Sciences, Allegheny-Singer Research Institute, 320 East
North Avenue, Pittsburgh, PA 15212, USA
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There is a pressing need for the identification of bio-
markers that can be used early in a patient’s treatment
to estimate the efficacy of IFN-b therapies in the treat-
ment of MS, as not all patients respond to this treat-
ment modality. This need is becoming even more
important as additional MS therapies become available,
and as the goal of personalized medicine is to find a
patient-specific therapy as early in treatment as possible
to minimize additional relapses. Thus, the objective of
this non-biased study approach, wherein we screened
for changes in gene expression of thousands of genes,
was to identify candidate biomarkers which can be
tested in future large-scale population studies early in
the treatment phase as a surrogate for efficacy.
Methods
This research protocol was approved by the Allegheny-
Singer Research Institute’s Institutional Review Board
(IRB). All study subjects were informed about the
research protocol and voluntarily enrolled in the study
by signing the IRB-approved consent forms.
Samples
Three peripheral blood samples were obtained from
each patient according to the following schedule: 1) pre-
treatment - the day prior to initiation of therapy with
IFN-b-1a (Avonex®; 30 mg intramuscular); 2) 24 hours
following initiation of therapy; and 3) 7 days following
the initiation of therapy. These specimens were used for
CD4+ T-lymphocyte gene expression studies for all
twenty patients, and for a final group of six patients
they were also used for fluorescence-activated cell sort-
ing (FACS)-based cell surface marker studies
Isolation of CD4+ T-Cell mRNA
Mononuclear cells were purified from fresh peripheral
blood specimens by centrifuging them onto a lympho-
cyte separation media (Ficoll-Paque: GE Healthcare; Pis-
cataway, NJ) density step gradient. CD4+ T-cells were
purified from the mononuclear cell fraction by negative
selection with magnetic beads (Miltenyi Biotec, Auburn,
CA), and were subjected to lysis in Rneasy Lysis buffer
(Qiagen; Valencia, CA). Messenger (m)RNAs were puri-
fied on oligo dT columns. Each mRNA sample was
tested for purity and integrity by microcapillary electro-
phoresis using an Agilent Bioanalyzer (Santa Clara, CA).
Any contaminating DNA detected by polymerase chain
reaction (PCR)-based amplification of housekeeping
genes, was removed by DNAse I treatment.
Gene Expression analysis using microarrays
Microarray analyses were performed using Illumina’s
Expression Beadchip as previously described [6]. Biotiny-
lated complementary (c) RNAs were prepared using 0.55
μg of total CD4+ T-cell mRNA using Illumina’s Total-
Prep RNA Amplification kit (San Diego, CA). Following
fragmentation, 0.75 μg of each cRNA prep was hybri-
dized to one of the bead chips. Arrays were scanned
using the Illumina Bead Station and the resultant data
were analyzed using Statistical Analysis of Microarrays
(SAM) software, applied to individual (not pooled)
specimens.
Flow Cytometry
Specimens from the final six patients enrolled in the
study were studied using flow cytometry. Their nega-
tively-selected, CD4+ T-cells were stimulated with phor-
bol 12-myristate 13-acetate (PMA, 10 ng ⁄ml) and
ionomycin (2 μmol/l) for 4 h in the presence of brefel-
din A (10 ng ⁄ ml; Sigma). After stimulation the cells
were washed with PBS and labeled with anti-CD4-FITC
and anti-IL-23R-PE at 4°C for 30 min. The cells were
then fixed and permeabilized prior to incubation with
anti-IL-12R2-APC (R&D Systems, Minneapolis, MN)
and immediately analyzed by flow cytometry. Data on
10,000 cell fluorescence events were acquired and ana-
lyzed using a FACSCalibur instrument (Becton-Dickin-
son, San Jose, Calif, USA), CellQuest™ and Paint-a-
gate™ software.
Immunoblotting
Total proteins were extracted from human CD4+ T-cells
negatively selected from the mononuclear white blood
cell fraction as described above and quantified using a
modified Bradford assay (Bio-Rad; Hercules, CA). Equal
quantities of protein extract were resolved by 12% SDS-
PAGE and transferred to nitrocellulose immobilization
membranes. The membranes were probed with antibo-
dies specific for IL-12Rb2, IL-23R, Stat4 or phosphory-
lated Stat4, conjugated with HRP-labeled secondary
antibody (R&D Systems, Minneapolis, MN), for signal
detection followed by densitometry.
Statistical Analysis
Data were expressed as the mean + SD. The difference
between groups was analyzed by Student’s t test, and p
< 0.05 was considered statistically significant.
Magnetic Resonance Imaging
MRI studies were performed prior to treatment and at
one year post treatment. Cerebral axial T1- and T2-
weighted imaging, and proton density and fluid attenu-
ated inversion recovery (FLAIR) axial sagittal imaging
was obtained for all patients. These were obtained on
either a Siemens (Erlangen, Germany) 1.5 Magnetom
units (D13B) or a General Electric (Milwaukee, WI)
signa unit (1.5 Tesla) with 5-mm cuts and 5-mm gaps.
All MRIs were reviewed by the senior investigator (T.S.).
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Results
We studied twenty relapsing-remitting MS patients (14
female and 6 male). All patients were sampled as
describe in Methods. All patients were treatment naïve
to IFN-b-1a (Avonex®; 30 mg intramuscular) and naive
to all other MS therapies, with the exception of one
patient who had remote prior exposure to glatiramir
acetate. All patients were free of relapses for at least 60
days prior to enrollment in the study. The average age
of the entire group was 37.1 years (range 26.6-57.5),
with an average disease duration of 6.7 years (range 0.3-
24.9). A subgroup consisting of the last 6 patients stu-
died underwent more detailed study (see below) and
consisted of 3 males and 3 females, average age 35.5
years (range 31.6-46.0), and average disease duration 4.5
years (range 0.5-25.5).
The results of the Illumina microarray experiments
designed to examine gene expression changes in the
CD4+ T-cells of MS patients following initiation of IM
IFN-b-1a (compared to pretreatment samples) were
highly remarkable for a mean 30-fold increase in IL-
12bR2 mRNA expression. We did not observe even 2-
fold increases in gene expression for: IL-12, IL-12Rb1,
IL-23, or other IL-23 receptor proteins. In addition, no
decreases in expression of 50% or greater following
initiation of therapy were observed with the sole excep-
tion of the mRNA for IL23R gene.
Based on the results of the microarray data obtained on
the first dozen patients enrolled in the study we designed
flow cytometric assays to characterize the IL-23R and IL-
12Rb2 cell surface markers of CD4+ isolated from the
PBMCs of the final six patients enrolled in the study.
These analyses detected a significant decrease in IL-23R+
CD4+ T-cells in 6 out of 6 patients at both 24 hours and
7 days post initiation of IM IFN-b-1a treatment (Figure
1) (range 11-75% decrease versus pre treatment). In addi-
tion, 4 of the 6 patients examined by flow cytometry for
their IL-12Rb2+CD4+ cells demonstrated increased num-
bers (range 16-65%) at both 24 hours and 7 days relative
to the pretreatment levels, while one patient showed
minimal changes (< 5% increase, patient 5) and the final
patient had an increased ratio of IL-12Rb2+CD4+ cells at
24 hours, but not 7 days (patient 2)(Figure 2).
Immunoblots were reliably produced for densitometry
measurements of Stat4 and phosphorylated Stat4 on
three of the six patients evaluated by FACS. Results for
all three patients demonstrated an increase in phospory-
lated Stat4 after treatment (Figure 3). Blinded reviews of
the charts of these 6 patients performed 12-16 months
after initiation of IM IFN-b-1a therapy to determine dis-
ease activity revealed that none of the patients experi-
enced relapses, received corticosteroids or developed
any new MRI lesions.
Discussion
This study was designed to broadly screen for early
time-point changes in the gene expression profiles of
CD4+ T-lymphocytes in MS patients receiving IFN-b
therapy as a means to identify candidate biomarkers of
response and nonresponse. The underlying hypothesis
being that alterations in the immune functionality of
CD4+ T-cells underlie the mechanism of action through
which IFN-b-1a alters the development of the autoim-
mune lesions characteristic of MS. Our study was too
small to provide a statistical correlate for lack of disease
progression (typically defined by the absence both of
relapsing events and the appearance of new MRI lesions
during therapy), with specific biomarkers which could
be identified early in the treatment regimen, however,
the results of our experiments suggest that IM IFN-b-
1a’s efficacy in reducing the number of exacerbation
events in MS may involve modulation of the number of
IL-12 and IL-23 receptors on CD4+ T-cells. This is par-
ticularly interesting as these two multi-protein receptors
share a common subunit, the IL-12Rb2. Thus, our find-
ings suggest that IFN-b may alter the ratio of the other
subunits of these two cytokine receptors although
through what mechanism remains to be determined.
Many other possible MOAs for IFN-b have been pro-
posed, mostly focusing on inflammation (inhibition of
leukocyte migration into the CNS, regulation of anti-
inflammatory cytokines such as IL-4 and IL-10, and pro-
posed pro-inflammatory cytokines such as IL-12, IL-17,
and IL-23) [7-9]. One previous report, also starting with
a nonbiased micro-array strategy, found an impressive
induction of mRNA for IL-12Rb2 in peripheral blood
mononuclear cells of MS patients treated with IFN-b,
and suggested a possible role of the IL-12 receptor (IL-
12R) in the MOA of IFN-b [8]. A separate study
reported that T-cells expressing the closely related
receptor for IL23 were less prevalent in IFN-b treated
patients [10]. Thus, our findings performed with purified
CD4+ T-cells are in accord with both of these studies
and support the concept that the T-cell response to
IFN-b likely involves complex changes in the overall
cytokine milieu and their receptors [4,11].
A recent study of IM IFN-b-1a-treated MS patients
showed a decrease in serum IL-12 after chronic treat-
ment, suggesting a possible dissociation between acute
and chronic effects [4]. However, an in vitro study of sti-
mulated CD45+ T-cells showed no change in the per-
centage of cells expressing IL-12 receptors after
treatment with IM IFN-b-1a [10], disagreeing with our
in vivo results.
Recently, due to the development of multiple thera-
peutic agents for MS, there has been an emphasis placed
on the development of biomarkers which could serve as
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early surrogates for the prediction of clinical response to
treatment. These biomarkers would provide for rapid
patient-specific tailoring of drug-treatment regimens to
minimize the time a patient would remain on a therapy
that would not be effective in ameliorating their disease.
Such biomarkers should ideally be identifiable through a
simple blood test. In terms of T-cell activities, there
have been reports suggesting the use of increased serum
Figure 1 Flow Cytometry of CD4+ IL23R+ T Cells. Expression of IL-23R subunit on the cell surface of CD4+T cells from MS patients
treated with beta-interferon. (A) Results of one representative patient. (B) Percentage of IL-23R+ T cells from MS patients. Values are expressed
as mean ± SEM. (C) Percentage of CD4+T cells expressing IL-23R in each MS patient treated with beta-interferon (n = 6).
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levels of IL-17F [9], and MxA protein levels [12] as bio-
markers for the effectiveness in IFN-b-treated MS
patients. Our universal finding (6/6) of decreased num-
bers of IL-23R+ CD4+ T-cells, combined with an
increased percentage of IL-12Rb2+ CD4+ T-lymphocytes
in most, but not all, IM IFN-b-1a-treated patients, none
of which experienced measurable disease progression for
a year or more following initiation of therapy, suggests
that these cell surface markers should be further investi-
gated in a large-scale prospective trial to determine their
potential efficacy to serve as biomarkers of therapeutic
effectiveness. It is important to stress that the number
of patients in this study was too small to seriously con-
sider attempting to identify a “responder” group. We did
review the clinical status of our patients in terms of
relapse and MRI changes, and found no difference in
Figure 2 Flow Cytometry of IL-12Rb2+ CD4+ T cells from MS patients before, 24 hr and 7 d after treatment with beta-interferon. (A)
Results of one representative patient. (B) Percentage of IL-12Rb2+ T cells from MS patients shows that at 24 hours post treatment that there is
an increase in this cell type that almost reaches statistical significance. Values are expressed as mean ± SEM. (C) Percentage of CD4+T cells
expressing IL-12b2 in each MS patient treated with beta-interferon (n = 6).
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terms of patients with significant changes in IL-12Rb2+
CD4+ cells versus those without.
We and others have previously used microarray
mRNA expression experiments as an unbiased means to
identify likely mediators of the therapeutic effect of IFN-
b [6]. Although this technology has been criticized for
being overly broad and merely exploratory, we find a
combined approach, in which microarray surveys are
used in the early stages of experimentation to provide
candidate gene-protein systems for subsequent hypoth-
esis-based characterization studies, serves as a powerful
strategy to divine the mechanism of action of systemic
therapeutics. This combined approach overcomes inves-
tigator bias that is associated with research that is purely
hypothesis based and provides an attractive strategy for
generating new discoveries with respect to the very large
number of unknown cellular activities that still exist.
Conclusions
In the current study we have observed significant shifts in
the numbers of IL-12 and IL-23 receptors on CD4+ T-
cells in patients receiving IM IFN-b-1a therapy. Our find-
ing of differential regulation of the IL-12 and IL-23
receptors among a small number of IM IFN-b-1a -treated
patients warrants further investigation. The central role
of IL-12 and IL-23 in the autoimmune process of MS
suggests measurement of IL-12 and IL-23 receptor activ-
ities may lead to biomarkers for responsiveness to IFN-b.
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Figure 3 IL-23R, IL-12Rb2, STAT4 and phospho-STAT4 expression on CD4+T cells from MS patients treated with b-interferon. Western
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patients before and after treatment with B-interferon. In each panel a polyacrylamde gel shows the results of one representative experiment.
Densiometry reports the relative intensity of all three patients. GAPDH was used as the internal loading control. (Data shown are all from the
same patient).
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